Psoriasis affects more than 40,000 people in Singapore and can lead to joint and cardiovascular complications. Clinical trials show the IL-17 inhibitor ixekizumab delivering strong skin clearance, shaping how moderate-to-severe psoriasis is treated.
Log In or Register as a healthcare professional to read the full article.
